Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Ulcerative colitis Stories

2011-07-21 16:11:00

HORSHAM, Pa., July 21, 2011 /PRNewswire/ -- Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy. REMICADE® was...

2011-07-19 11:57:28

Westie Foundation of America reports preliminary research progress in dog breed's health and potential implications The Westie Foundation of America (WFA) announced today preliminary findings in two major studies involving the health of West Highland White Terriers also known as Westies. Findings in these and other studies of Westies and other dogs may hold answers for similar human conditions like Inflammatory Bowel Disease (IBD). The studies are jointly funded by the WFA and the AKC Canine...

2011-07-18 06:00:00

PHILADELPHIA, July 18, 2011 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Lialda(R) (mesalamine) Delayed Release Tablets for the maintenance of remission in patients with ulcerative colitis. This approval is based on results from a six-month study demonstrating the safety and effectiveness of Lialda in maintaining endoscopic remission in adult...

2011-07-18 06:00:00

PHILADELPHIA, July 18, 2011 /PRNewswire/ -- Shire plc (LSE: SHP; NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Lialda® (mesalamine) Delayed Release Tablets for the maintenance of remission in patients with ulcerative colitis. This approval is based on results from a six-month study demonstrating the safety and effectiveness of Lialda in maintaining endoscopic remission in adult...

2011-07-12 14:26:00

NEW YORK, July 12, 2011 /PRNewswire-USNewswire/ -- The Crohn's & Colitis Foundation of America today announced that it has opened enrollment for CCFA Partners, a comprehensive Internet-based registry designed to study thousands of patients with Crohn's disease or ulcerative colitis under a single research initiative. These chronic and often painful digestive diseases, collectively known as inflammatory bowel diseases (IBD), affect over 1.4 million Americans. Unlike prior research,...

2011-07-06 13:00:00

NEW YORK, July 6, 2011 /PRNewswire/ -- Coronado Biosciences, a biopharmaceutical company focused on novel immunotherapy agents for inflammatory diseases and cancer, today announced that it closed a $25.8 million Series C financing led by National Securities Corporation. Coronado plans to use the proceeds from the financing to advance its pipeline, including funding a Phase II study of the company's lead development candidate, CNDO-201 for the treatment of Crohn's Disease and a Phase I/II...

2011-06-22 02:00:00

HEIDELBERG, Germany, June 22, 2011 /PRNewswire/ -- - Primary Endpoint Met Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced positive topline results from a Phase IIb clinical trial with its lead product, LT-02, in patients with ulcerative colitis. LT-02 is a controlled release formulation of phosphatidylcholine that has been specifically designed to treat ulcerative colitis by improving the barrier...

2011-06-14 05:18:00

UPPER SADDLE RIVER, N.J., June 14, 2011 /PRNewswire/ -- WellApps, Inc. announced today the newest release of GI Monitor, its symptom tracking app for (IBD) Crohn's and Ulcerative Colitis. Co-Founder Edward Shin, MD, says, "We're particularly excited about the new release since GI Monitor has recently quadrupled its user-base. This scale is providing some powerful real-time data and we know what an engaged mobile community can mean for patients." One of those patients is Brett Shamosh,...

2011-06-05 08:36:00

NEW ORLEANS, June 5, 2011 /PRNewswire/ -- Chuck Wielgus, Executive Director of USA Swimming, was named this year's Great Comebacks® National Award recipient at a ceremony held in conjunction with the Wound, Ostomy and Continence Nurses (WOCN) Society's 43rd Annual Conference in New Orleans, LA. The Great Comebacks® Program, which provides support for people living with intestinal diseases that can lead to ostomy surgery, annually honors outstanding...

2011-06-02 15:56:26

The first study of the social and ethical issues associated with a provocative approach to treatment for ulcerative colitis has found that the majority of potential patients are eager for what is now called "fecal microbiota transplantation" to become available, although many have concerns about donor selection, screening, and methods of delivery. Bacterial aggregates derived from fecal matter have been used sporadically to treat gastrointestinal disease for more than 50 years. These were...